סוניטיניב תרו 25 מג
taro international ltd, israel - sunitinib - קפסולה קשיחה - sunitinib 25 mg - sunitinib
סוניטיניב תרו 37.5 מג
taro international ltd, israel - sunitinib - קפסולה קשיחה - sunitinib 37.5 mg - sunitinib
סוניטיניב תרו 50 מג
taro international ltd, israel - sunitinib - קפסולה קשיחה - sunitinib 50 mg - sunitinib
דסטיניב סנדוז 100 מג
novartis israel ltd - dasatinib - טבליות מצופות פילם - dasatinib 100 mg - dasatinib
דסטיניב סנדוז 140 מג
novartis israel ltd - dasatinib - טבליות מצופות פילם - dasatinib 140 mg - dasatinib
דסטיניב סנדוז 20 מג
novartis israel ltd - dasatinib - טבליות מצופות פילם - dasatinib 20 mg - dasatinib
דסטיניב סנדוז 50 מג
novartis israel ltd - dasatinib - טבליות מצופות פילם - dasatinib 50 mg - dasatinib
דסטיניב סנדוז 70 מג
novartis israel ltd - dasatinib - טבליות מצופות פילם - dasatinib 70 mg - dasatinib
אירסה
astrazeneca (israel) ltd - gefitinib - טבליות מצופות פילם - gefitinib 250 mg - gefitinib - gefitinib - iressa is indicated as monotherapy for the continued treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of both platinum-based and docetaxel chemotherapies who are benefiting or have benefited from iressa. results from two large controlled randomized trials in first-line treatment of non-small cell lung cancer showed no benefit from adding iressa to doublet platinum-based chemotherapy.iressa is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with activating mutations of egfr-tk.
טרסבה 150 מג
roche pharmaceuticals (israel) ltd - erlotinib as dihydrochloride - טבליות מצופות פילם - erlotinib as dihydrochloride 150 mg - erlotinib - erlotinib - tarceva is indicated for the treatment of patients with locally advanced or metastatic non - small cell lung cancer after failure of at least one prior chemotherapy regimen. tarceva is indicated in combination with gemcitabine for the first-line treatment of patients with locally advanced unresectable or metastatic pancreatic cancer.tarceva® monotherapy is indicated for the maintenance treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc) whose disease has not progressed after four cycles of platinum-based first-line chemotherapy. tarceva is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with egfr activating mutations.